Navigation Links
UC Researchers Find Potential Drug Target For SARS

Researchers at the University of Illinois at Chicago in collaboration with their colleagues from two other institutions have found the structure of an enzyme in the virus that causes SARS//, severe acute respiratory syndrome. The researchers, who have detailed these findings in the March 27 issue of the Proceedings of the National Academy of Sciences, hope that this could form a new drug target for drug makers.

"By unlocking the three-dimensional structure of this enzyme -- known as papain-like-protease (PLpro) -- we now have a molecular road map to design new drugs that could potentially treat SARS-infected patients, or perhaps patients suffering from other SARS-related illnesses such as the common cold, bronchitis or pneumonia," commented Andrew Mesecar, associate professor of pharmaceutical biotechnology in the UIC College of Pharmacy. "We are attempting to use the same approach that has been accomplished in designing effective drugs against HIV protease, which has led to the development of new drugs to fight the AIDS virus." SARS caused havoc in 2003 when it was first reported from Asia. Within a short span of time, the disease had sp[read to 29 countries in North and South America, Europe and Asia before it was finally controlled. It begins as fever, headache and body aches and severe cases develop diarrhea and pneumonia. In the 2003 outbreak, 774 people succumbed to the disease, which was diagnosed in 8,098 people worldwide, according to the World Health Organization. Mesecar said that the papain-like-protease enzyme forms the crux which is vital for trhe replication of the virus. Stooping this enzyme could inhibit the disease, he said. Contact: Sam Hostettler samhos@uic.edu 312-355-2522 University of Illinois at Chicago Source: Eurekalert
'"/>




Page: 1

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers trick Alzheimers Enzyme
4. Researchers find new HIV hiding place
5. New Hair in 15 Days Could Now Be A Possibility Say Researchers
6. Researchers developed world’s smallest toothbrus
7. Researchers discover receptor cells that can cause epilepsy
8. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
9. Researchers reversed the process of memory loss
10. Researchers Identify Key Gene That May Help Brain Treatment
11. Researchers Discover Protein That Causes Malaria
Post Your Comments:
(Date:7/25/2008)...ewswire-FirstCall/ -- Thoratec,Corporation (Nasdaq...l,circulatory support therapies to save, support a... will report its operating results for the second,...rsday, July 31., The company will hold a conferen...ting activities to all interested parties at 1:30 ...
(Date:7/25/2008)...nsumers tips and encourages them to, ,Speak Up,(T...July 25 /PRNewswire-USNewswire/ -- The Pennsylvani...l Patient Safety Day" which,is a national effort t...pate fully in their healthcare by asking questions...ery or illness., "We understand the important rol...
(Date:7/25/2008)...ing Exclusivity Begins -, CORONA, Calif., July 25... Inc. (NYSE: WPI ), a leading specialty pharmaceu... has commenced commercial,shipment of its Omeprazo...g,strength from its Davie, Florida manufacturing f...s 180 days of marketing exclusivity for being the,...
(Date:7/25/2008)...iance to be presented at Fenway Park ... 25 /PRNewswire/ -- CVS/pharmacy announced today,t... million in just 21 days,through its annual in-sto...the seventh year of the annual fundraising effort ...or ALS research. This year,s fundraiser took,place...
Breaking Medicine News(10 mins):Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2
...ve been killed in Turkey with the object of combat...untry. This has been revealed by the Turkish Natio...ion has been detected in as many as 13 provinces i...uspected cases. The provinces where the bird flu h...
...eing sued by four Marlboro smokers for hi-tech scr...r. The four people are demanding that the company .... //If this were to be brought into force, it will... of early detection. The company has been accused ...
... prove to be as beneficial to people suffering fro...is has been revealed by a Dutch study. The same am...tients who underwent these two therapies, when com...t at all. A combination of both the treatments did...
...nce a day for treating AIDS is sought to be develo...Gilead Sciences Inc. The regimen of three drugs wi... receive a formal approval towards end 2006. //As ...fected by AIDS, with the poor nations accounting f...
Other Medicine News:
(Date:7/22/2008)...nin Medical, a leading innovator,of physiological ...ntered,the clinical testing phase with its breakth...tion. Today,s most common application for this,tec...al blood oxygenation,in the brain -- cerebral oxim...going clinical study at the,Duke University Medica...
(Date:7/22/2008)...ma Exhibits Excellent Drug-Like ...itiation of Phase II Clinical Trials -, RESEARCH ...x BioPharma,Inc., a clinical stage company develo... diseases of the central nervous system, today ann...TM) into Phase II trials for the,treatment of depr...
(Date:7/22/2008)...and pegylated enzyme produces significantly enh... - Pegylated enzyme well tolerated -...lozyme Therapeutics,Inc. (Nasdaq: HALO ), a biop...ng products targeting the extracellular matrix, to...nical animal efficacy data,for its pegylated-rHuPH...
(Date:7/22/2008)... Risk Based on Clinical Data, Preventive Measur...WALTHAM, Mass., July 22 /- ...nounced the launch of an enhanced test report,form... Health Genetic Test.,The test is currently market...netic Test by Quixtar/Amway. The new report will i...
Breaking Medicine Technology:Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Over 30 New Studies of Oral Xeloda 28R 29 Featured at the 2008 Gastrointestinal Cancers Symposium 1270 1Over 30 New Studies of Oral Xeloda 28R 29 Featured at the 2008 Gastrointestinal Cancers Symposium 1270 2Over 30 New Studies of Oral Xeloda 28R 29 Featured at the 2008 Gastrointestinal Cancers Symposium 1270 3Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference 2730 1U S Department of Labor Announces 241 25 Million to North Carolina to Help Trade Affected Workers Pay for Health Insurance 10083 1U S Department of Labor Announces 241 25 Million to North Carolina to Help Trade Affected Workers Pay for Health Insurance 10083 2Surprise in Lab Helps ID Drug to Fight ALS 10080 1Surprise in Lab Helps ID Drug to Fight ALS 10080 2
... Diamyd Medical AB (<a target="_blank" href=,"http...AM B;, www.otcqx.com ,ticker DMYDY) , , STOCKHOL...on,made in Linkoping, Sweden at the Sweden-Seattle... Johnny Ludvigsson, the Principal,Investigator in ...e,II study in type 1 diabetes, presented potential...
...DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Argos...data on the immunosuppressive,properties of solubl...g to be held in San Francisco, May 5-9. The presen...sts at the University of,Western Ontario., "These ...raft,survival in transplantation, and that it can ...
Other Medicine Technology:Revolutionary Immunologic Data Explains Function of Diamyd Diabetes,Vaccine 2Revolutionary Immunologic Data Explains Function of Diamyd Diabetes,Vaccine 3Revolutionary Immunologic Data Explains Function of Diamyd Diabetes,Vaccine 4Revolutionary Immunologic Data Explains Function of Diamyd Diabetes,Vaccine 5Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007 2
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: